ROXUDO
ROXADUSTAT · by CCL
Composition
Tab 20 mg/50 mg/70 mg/100 mg/150 mg: Roxadustat 20 mg/50 mg/70 mg/100 mg/150 mg
Indications & Dosage
Symptomatic anaemia associated with chronic kidney disease in patients not currently treated with an erythropoiesis-stimulating agent (initiated by a specialist): Adult (body-weight up to 100 kg): Initially 70 mg 3 times a week, adjusted according to response; usual maintenance 20-400 mg 3 times a week, dose adjusted at intervals of 4 weeks to achieve haemoglobin concentration of 10 to 12 g/dL. Discontinuation treatment if adequate increase in haemoglobin concentration not achieved in 24 weeks. Adult (body-weight 100 kg and above): Initially 100 mg 3 times a week, adjusted according to response; usual maintenance 20-400 mg 3 times a week, dose adjusted at intervals of 4 weeks to achieve haemoglobin concentration of 10 to 12 g/dL. Discontinuation treatment if adequate increase in haemoglobin concentration not achieved in 24 weeks. Symptomatic anaemia associated with chronic kidney disease in patients currently treated with an erythropoiesis-stimulating agent (initiated by a specialist): Adult: (consult product literature).
Precautions
Active infection. history of seizures, epilepsy and other medical conditions associated with a predisposition to seizures. risk factors for venous thromboembolism. Caution in moderate hepatic impairment; use half the normal starting dose, avoid in severe impairment. Pre-treatment screening: Ensure adequate iron stores before treatment. Monitor haemoglobin concentration every 2 weeks until the desired haemoglobin concentration is achieved and stabilised, then every 4 weeks thereafter or as clinically indicated.
Interactions
Drugs highly bound to red cells e.g. Cyclosporin.
Pregnancy
Avoid
Lactation
Avoid
Side Effects
Constipation, diarrhoea, embolism and thrombosis, headache, hyperkalaemia, hypertension, insomnia, nausea, peripheral oedema, seizure, sepsis, increased risk of infection, vomiting. Rare: Hyperbilirubinaemia.